Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Investor webinar reminder and presentation

Highlights:

- **Shareholders and interested investors are invited to join Neurizon's investor webinar featuring CEO Dr Chris Bremer and CFO Mr Dan O'Connell**
- **Investor webinar to be held on 5 November 2026 at 1.00pm (Melbourne time) to provide further details on Company's funding strategy and recent corporate developments**

05 November 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the attached investor presentation ahead of its shareholder webinar scheduled for today, Thursday, 5 November 2026.

The presentation provides an overview of the Company's recent capital raise, including the $4.3 million placement and proposed $2 million Share Purchase Plan (SPP), alongside the strategic rationale for redeeming the remaining Obsidian convertible notes and strengthening Neurizon's funding position ahead of the anticipated HEALEY ALS Platform Trial topline results in late Q2 CY2027.

The presentation also outlines the Company's funding flexibility, ongoing progress, and key development milestones as Neurizon advances NUZ-001 towards its first randomised efficacy readout.

Chief Executive Officer, Dr Chris Bremer, and Chief Financial Officer, Dan O'Connell, will host the webinar and provide shareholders with further commentary on the Company's capital management strategy, the SPP and its clinical development priorities.

Webinar details:

- **Date:** 5 November 2026
- **Time:** 1:00pm AEDT
- **Presenters:** Dr Chris Bremer, CEO, and Dan O'Connell, CFO
- **Registration:** https://bit.ly/2026CorporateUpdate

Shareholders and investors are encouraged to register in advance and submit questions ahead of the webinar. A recording will be made available following the event.

-ENDS-

This announcement has been authorised for release by Dr Chris Bremer, Chief Executive Officer, on behalf of the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Marketing & Corporate Affairs
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Investor Relations
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited

Neurizon

A strengthened funding position ahead of HEALEY trial topline



Shareholder webinar – 5 November 2026

Dr Chris Bremer, Chief Executive Officer
Dan O'Connell, Chief Financial Officer

ABN 35 094 006 023

Disclaimer

This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the "Company"). This disclaimer applies to the presentation and all information contained in it. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company.
The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.


Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1933 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Neurizon

Our Vision



To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases.

Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases

Lead ALS/MND program in Phase 2/3, with topline results expected in late Q2 CY2027

WHO WE ARE

Neurizon is developing therapies for neurodegenerative diseases, with its lead investigational therapy, NUZ-001, currently being evaluated in ALS/MND.

NUZ-001 is an oral small molecule with preclinical evidence demonstrating effects on cellular protein clearance pathways associated with neurodegeneration.

ASX: NUZ · OTCQB: NUZTF

LEAD ASSET: NUZ-001

Investigational oral small molecule being developed initially in ALS/MND and currently evaluated in the Phase 2/3 HEALEY ALS Platform Trial.

NUZ-001 IN ALS/MND AT A GLANCE

ORAL	PHASE 2/3	250	LATE Q2 2027
Once-daily administration	HEALEY ALS Platform Trial	Regimen I participants, randomised 3:1	Expected topline

BUILT AROUND THE CLINICAL OPPORTUNITY

CLINICAL VALIDATION	API SUPPLY ESTABLISHED	EXPANDED EVIDENCE	NEAR-TERM CATALYST	BROADER POTENTIAL
250-participant Phase 2/3 HEALEY	Long-term supply agreement with Elanco	NIH-funded EAP up to 200 participants	Topline expected late Q2 CY2027	Preclinical evidence in other neurodegenerative diseases

Why look now

A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection

Late Q2 2027

Expected topline from the 250-participant Phase 2/3 ALS trial.

NIH-Funded EAP

for NUZ-001 for 200 participants up to 96 weeks.

Funding secured

Fully funded through to HEALEY topline results. Outstanding convertible notes redeemed.

1

Clinical advancement

A 250-participant randomised Phase 2/3 enrolled in less than 5 months – record enrolment for the HEALEY ALS Platform Trial.

NIH-funded EAP for NUZ-001.

2

Supply chain readiness for scale

Long-term supply agreement with Elanco for GMP API supply and registration-scale manufacturing.

3

Evidence-led development

Promising Phase 1 signals, with an exploratory biomarker panel built into ongoing Phase 2/3 trial. HEALEY provides established clinical infrastructure across 78 US sites led by Mass General Brigham.

4

Strategic and commercial optionality

An upcoming, randomised Phase 2/3 dataset that will inform Neurizon's regulatory, partnering and commercial strategy.
Total addressable market (TAM) opportunity of ~US$5bn[1].

[1] Illustrative US TAM of approximately US$5 billion based on projected 2026 US ALS prevalence of approximately 34,720 adults (CDC National ALS Registry) and assumed annual net pricing of US$150,000 per patient.

Placement and Share Purchase Plan (SPP) overview

$6.3m in new equity targeted, with the convertible notes now fully redeemed

PLACEMENT

$4.3m

Firm commitments at 6.8c per share from new and existing institutional, sophisticated and professional investors

SHARE PURCHASE PLAN

Target $2m

Eligible shareholders can apply for up to $30,000 at the same 6.8c price, without brokerage

OPTIONS

1 for 1

One free option per new share, exercisable at 12c, expiring 18 months from issue (subject to shareholder approval)

CONVERTIBLE NOTES ON ISSUE

Nil

Remaining Obsidian notes redeemed, taking total redemptions to 1,750,000 of 3,575,500 issues. Drawdown resolution withdrawn from AGM

✓

Remain fully funded through to HEALEY topline in late Q2 CY2027 and with no convertible notes held by Obsidian.
Funding strategy to topline readout include one further facility drawdown (not before April 2027 and subject to shareholder approval), with the ability to displace it with alternative funding – **Multiple avenues are under development and assessment.**

Why we acted now

Underpinned by clinical and operational momentum

WHERE THE PROGRAM IS

1 **Fully enrolled with topline pending**

HEALEY Regimen I: 250 participants in under five months, a record for the platform with topline results remaining on track for late Q2 CY2027

2 **Regulatory clarity**

FDA Type C feedback supports the potential for Regimen I to serve as a single registrational study, subject to substantial evidence of effectiveness

3 **Operational readiness**

Long-term GMP supply agreed with Elanco; NIH-funded Expanded Access Program for ~200 patients in preparation

THE OPERATING BACKDROP

Capital Structure Simplification

The convertible note facility created uncertainty around the Company's capital structure and the potential dilution. Removing the notes from the structure removes this uncertainty.

The opportunity

A 56% share price recovery from 1 September to 28 October 2026 following a standstill with Obsidian [1]. Neurizon performed strongly against peer group over both short and long term (3, 6 and 12 months)[2]

Market Positioning

With a fully enrolled potentially registrational trial that will read out in late Q2 CY2027, Neurizon is very well positioned. The simplified capital structure and the reduced selling should allow better recognition of this.

[1] 1 September 2026 was the last day of selling by Obsidian prior to the agreed standstill between Obsidian and Neurizon.
[2] Source: ASX closing prices; company analysis. Peers: Prescient, Alterity, Amplia, Noxopharm, Race Oncology, Arovella, Dimerix and Imugene.

SPP rationale and overview

Acting in the best interest of shareholders

1 Outstanding Obsidian notes redeemed

All remaining notes redeemed for cash: 1,750,000 in total have been bought back rather than converted, so no conversion shares can be issued

2 Equal opportunity for participation

The SPP offers the same 6.8c price and the same 1 for 1 options, up to $30,000 per holder, without brokerage

3 Continued engagement with our shareholders

The AGM drawdown resolution is withdrawn. Any future drawdown needs shareholder approval, after the Board has considered all alternatives

4 Board and management alignment

Directors, management and their direct networks have contributed strongly to this raise.

SPP offer metrics:

20.9%

discount to last close of 8.6c (28 October 2026)

18.9%

discount to the 5-day VWAP of ~8.38c

6.8c

in line with the 3-month VWAP (6.80c) and above the 6-month VWAP (6.70c)

Indicative timetable

Event	Dates (Melbourne time)
SPP record date	7.00pm, Friday, 30 October 2026
Announce results of Placement, announce SPP, trading halt lifted and return to trading on the ASX	Pre-market Monday, 2 November 2026
Settlement of New Shares under the Placement[2]	Friday, 6 November 2026
Allotment date and expected normal trading of New Shares under the Placement[2]	Monday, 9 November 2026
SPP opening date and New Options offer opening date	Monday, 16 November 2026
Annual General Meeting	Wednesday, 25 November 2026
SPP closing date	5.00pm, Friday, 4 December 2026
Results of SPP announced	Friday, 11 December 2026
Issue of New Shares under SPP	Friday, 11 December 2026
New Shares under SPP commence trading on ASX	Monday, 14 December 2026
Despatch of holding statements in respect of SPP New Shares	Tuesday, 15 December 2026
General Meeting to approve Director Participation and the New Options	Thursday, 17 December 2026
Issue of New Shares under Director Participation and issue of New Options under Placement and SPP[3]	Late-December 2026
Expected normal trading of New Shares under Director Participation and New Options under Placement and SPP[3]	Late-December 2026

1. The above timetable is indicative only and the Company reserves the right to withdraw the Placement or vary the timetable for the Placement at any time before the issue of the relevant securities without notice, subject to the Listing Rules and the Corporations Act and other applicable laws. The Company reserves the right to close the SPP early, extend the SPP closing date or to withdraw the SPP, in its sole and absolute discretion, by lodging an announcement with the ASX. The commencement of trading and quotation of New Shares and New Options is subject to ASX confirmation. The Company gives no assurance that such quotation will be granted.
2. Excluding New Shares to be issued to Directors as subject to shareholder approval at the General Meeting.
3. Subject to shareholder approval being obtained at the General Meeting and quotation condition being satisfied (as applicable).

Near term value catalysts

Multiple workstreams underway to drive shareholder value

Area	Development	Indicative timing
Preclinical	Further Preclinical Insights into Mechanism of Action of NUZ-001	Mid Q4 CY2026
Clinical	First HEALEY Regimen I participant completes Randomised Treatment phase and enters A ctive Treatment Extension	Mid Q4 CY2026
Corporate	Quarterly R&D Funding acceleration (Dare Strategic Loan Facility)	Mid Q4 CY2026
Corporate	AGM & AGM Presentation	Mid Q4 CY2026
Corporate	SAB and KOL formation	Late Q4 CY2026
Corporate	FY2026 R&D Tax rebate – refund from Australian Taxation Office	Late Q4 CY2026
Corporate	Presentation at International Symposium on MND/ALS	Late Q4 CY2026
Clinical	First EAP participant enrolled	Mid Q1 CY2027
CMC	First boundary batch manufactured	Q1 CY2027
Regulatory	FDA Type D Meeting	Q1 CY2027

Clinical, corporate, regulatory and scientific workstreams underway to unlock shareholder value and further strengthen readiness.

A roadmap to topline readout and beyond

Multiple material developments converging over the coming quarters



Expanding Pre-Clinical Evidence

Addressing MOA questions

Expanded Access opens

Adds long-term safety and real-world data in a broader population

Trial completion and database lock

Final step before unblinding

HEALEY topline

First randomised efficacy data: the defining event

Regulatory engagement on the data

Sets the route and timing to market

Timing reflects current company guidance and planning, and may change. EMA advice and Expanded Access timing to be confirmed by management before external use.


Investment summary

A defining randomised readout in late Q2 CY2027, with groundwork in place

Late Q2 CY2027

HEALEY Regimen I topline: the first randomised efficacy data for NUZ-001.

1. A 250-participant randomised Phase 2/3 in ALS, efficiently run
2. Record enrolment within the HEALEY platform, in under five months
3. Early clinical signals that shaped the Phase 2/3 trial design
4. Supply, manufacturing and biomarker work already in place
5. Established regulatory foundations with partnering and commercial optionality



Thank You

Registered Address:
Suite 2, Level 11, 385 Bourke Street
Melbourne, VIC 3000 Australia

+61 (3) 9692 7222

enquiries@neurizon.com

Neurizon